CALGB40502_2D: CALGB40502, figure 2D

CALGB40502_2DR Documentation

CALGB40502, figure 2D

Description

Kaplan-Meier digitized data from CALGB40502, figure 2D (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.

Usage

CALGB40502_2D

Format

A data frame of 542 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (nab_paclitaxel, p1)

Source

Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33: 2361–9.

Examples

summary(CALGB40502_2D)

kmplot(CALGB40502_2D)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.